Lipid Nanoparticles Immunogenicity and Toxicity

Enhance Your Prediction of PKPD, Accurate Dosing Regime and Immuno-Modulation of LNP for Long-Term Patient Safety and Potency Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. The highly anticipated Lipid Nanoparticle Immunogenicity and Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology, immunogenicity, bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.